Epoprostenol now the focus of numerous clinical trials

William A. Check
JAMA. 1981;245(24):2481-2483. doi:10.1001/jama.1981.03310490003001.
Text Size: A A A
Published online


Evidence is fast accumulating on the therapeutic value of one of the newest members of the prostaglandin family, epoprostenol, which was discovered in 1976.

In the United States recently to deliver a lecture, John Vane, DSc, group research director at the Burroughs Wellcome Foundation, Beckenham, England, described for JAMA MEDICAL NEWS some of the clinical trials in which the compound has proved its value as an inhibitor of platelet aggregation. Vane received the Lasker Award in 1977 for his prominent role in the discovery of epoprostenol, also known as PGI2 and more commonly as prostacyclin.

Other information on epoprostenol comes from a recent conference on prostaglandins in cerebrovascular and thrombotic disorders held in Chicago under the auspices of Rush Medical College and Northwestern University Medical School.

Epoprostenol was actually discovered by Vane and Salvador Moncada during their search for thromboxane, the prostaglandin that promotes aggregation of platelets, in the endothelium


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.